Terug naar bedrijfspagina

Nieuws over BioSenic (Bone Therapeutics)

12/04/2024 BioSenic - provides further information on its restructuring plan (12.04.2024)

11/04/2024 BioSenic - and its restructuring practitioner (Me Yves Brulard) submit a global restructuring plan covering the years 2024-2030 to the Enterprise Court of Nivelles (11.04.2024)

12/03/2024 BioSenic - releases details of optimized administration approach ahead of planned Phase 3 trial of OATO for chronic graft-versus-host disease (12.03.2024)

02/02/2024 BioSenic - raises €500,000 in private placement of new shares with established new investors (02.02.2024)

30/01/2024 Biosenic - BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform (30.01.2024)

25/01/2024 BioSenic - présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 (25.01.2024)

23/01/2024 BioSenic - files for additional patent protection following new clinical evidence of efficacy for JTA-004 in osteoarthritis (23.01.2024)

15/01/2024 BioSenic - reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment (15.01.2024)

09/01/2024 BioSenic - signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds (09.01.2024)

08/12/2023 BioSenic - ERRATUM - on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease (08.12.2023)

06/12/2023 BioSenic - on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease. (06.12.2023)